Common TitleDUALIS
Official Title Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study
Phase Phase III
Treatments
Darunavir![Darunavir Prezista](https://cdn.hiv.uw.edu/css/images/drugs/9.png)
, ![Darunavir Prezista](https://cdn.hiv.uw.edu/css/images/drugs/9.png)
Darunavir
Tradename:PrezistaOther Names:DRVClass:Protease Inhibitors (PI)Dolutegravir![Dolutegravir Tivicay](https://cdn.hiv.uw.edu/css/images/drugs/14.png)
![Dolutegravir Tivicay](https://cdn.hiv.uw.edu/css/images/drugs/14.png)
Dolutegravir
Tradename:TivicayOther Names:DTGClass:Integrase Inhibitors (INSTI)Categories Treatment-ExperiencedSwitch/SimplificationDual Therapy
Funding
IndustryJanssen Pharmaceuticals and ViiV Healthcare
Non-IndustryTechnical University Munich
References
- Spinner CD, Kümmerle T, Schneider J, et al. Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study. Open Forum Infect Dis. 2020;7(9):ofaa356.